The target antigens in multiple early-phase CAR T-cell clinical trials for pancreatic cancer include mesothelin (MSLN), prostate stem cell antigen (PSCA), carcinoembryonic antigen (CEA), HER2, MUC1, and CD133. The gene discussed is PSCA; the disease is pancreatic neoplasm.